AAPM Task Group Report 274: Fluence rate dosimetry for photodynamic therapy (PDT)

Med Phys. 2025 Jan 15. doi: 10.1002/mp.17613. Online ahead of print.

Abstract

Photodynamic therapy (PDT) is a treatment modality clinically approved for several oncologic indications, including esophageal and endobronchial cancers, precancerous conditions including Barrett's esophagus and actinic keratosis, and benign conditions like age-related macular degeneration. While it is currently clinically underused, PDT is an area of significant research interest. Because PDT relies on the absorption of light energy by intrinsic or administered absorbers, the dosimetric quantity of interest is the absorbed energy per unit mass of tissue, proportional to the fluence rate of light in tissue. It has been demonstrated that the fluence rate at the tissue surface may differ significantly from the incident irradiance of light because of multiple scattering and absorption, both of which may vary among patients and tissue types. This report will review the current state-of-the-art fluence rate dosimetry technology. It will describe the two types of detectors currently available for fluence rate measurement, scattering-tip and fluorescence-based detectors, and review their principles of operation. The report will recommend strategies to establish calibration and quality assurance procedures for clinical fluence rate dosimetry equipment, and it will establish guidelines for clinical implementation of fluence rate dosimetry.

Keywords: TG274; in vivo dosimetry; light fluence; photodynamic therapy.